DAPA-HF Response Predictor Calculator
Patient profile
Enter baseline characteristics from the clinical assessment. The form summarizes the profile; it does not calculate an individualized treatment-response probability.
Clinical context
The DAPA-HF randomized trial evaluated dapagliflozin 10 mg once daily in patients with symptomatic heart failure and LVEF ≤40%, on recommended background therapy. Over a median 18.2 months, the primary composite of worsening heart failure or cardiovascular death occurred in 16.3% of the dapagliflozin group and 21.2% of the placebo group (hazard ratio 0.74; 95% CI 0.65–0.85).
What this tool can and cannot tell you
- It can collect and display selected baseline variables relevant to the clinical profile.
- It does not reproduce a validated DAPA-HF treatment-effect model or estimate an individual probability of response.
- Baseline risk and absolute benefit are not the same as a validated prediction of differential treatment response.
- Diabetes status alone should not determine whether an otherwise eligible patient is considered for dapagliflozin.
Practical use
Use the profile as a documentation aid only. Treatment decisions should follow current heart-failure guidelines and product information, with assessment of renal function, blood pressure, volume status, concomitant therapy, and patient-specific contraindications or precautions.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.